HLA class II antibodies in the treatment of hematologic malignancies.
Promising results have suggested human leukocyte antigen (HLA) class II as potential target for antibody-based lymphoma therapy. Thus, antibodies against HLA class II induced apoptosis in vitro, as well as complement-dependent cytotoxicity (CDC) and effector cell-mediated cytotoxicity (ADCC). Furthermore, animal models demonstrated strong antitumor effects in vivo. Importantly, early clinical studies with antibodies Lym-1 or Hu1D10, both against HLA-DR variants, suggested therapeutic potential. However, the increased risk of serious toxicity may require an improved understanding of the clinically relevant mechanisms of action of HLA class II-directed antibodies, which may then allow generation of optimized antibody constructs to achieve optimal therapeutic efficacy.
Dechant
Michael
M
Department of Medicine III, University Erlangen-Nuremberg, Germany.
Bruenke
Joerg
J
Valerius
Thomas
T
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000276:immunology; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D006684:HLA-DR Antigens / Q000276:immunology; D019337:Hematologic Neoplasms / Q000628:therapy*; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D006801:Humans
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II